How Fast Does Basal Cell Carcinoma Spread?

Basal cell carcinoma grows slowly compared with most cancers, averaging roughly 0.7 mm per month along its longest dimension in a pooled analysis of available studies. That pace is part of why BCC has a reputation as the “harmless” skin cancer, but it is also why so many tumors quietly reach a large size before anyone takes action. The reality of BCC spread is more nuanced than a single growth rate suggests, because the subtype of tumor, its location, and the person’s immune status all shift that number considerably.

Measured Growth Rates

Pinning down exactly how fast a BCC grows is harder than it sounds. Researchers cannot ethically leave a confirmed cancer untreated for months just to measure it, so most data comes from the gap between a patient’s first specialist consultation and the date of surgery. A meta-analysis pulling together published studies calculated a mean growth rate of 0.71 mm per month along the tumor’s longer axis.¹ For perspective, that is a bit less than a millimeter a month, or roughly the width of a pencil tip every four weeks.

Location matters. BCCs around the eye, where the skin is thin and tissue planes are tight, appear to expand their surface area at about 11 mm² per month.² That may not sound dramatic, but around the eyelid even small growth can threaten structures that are difficult to reconstruct surgically. A community-based study tracking BCC size over time found that tumors roughly doubled in their mean size over five to ten years of observation relative to their size at initial presentation.³ That is a meaningful change, but spread over years rather than weeks.

Not every BCC grows at a steady clip, either. In a study comparing patients who waited different lengths of time before treatment, those whose tumors had grown had a median delay of about six months, while patients whose tumors stayed the same size or even shrank had a median delay of about two and a half months.⁴ The takeaway is that some BCCs genuinely sit still for stretches, while others creep forward. Growth is the trend, but it is uneven.

Why Some BCCs Grow Faster Than Others

The word “basal cell carcinoma” covers a family of tumors, not a single entity. Pathologists classify them into subtypes based on the pattern of cells under the microscope, and that pattern has a real relationship to how aggressively the tumor behaves. The morpheic (sometimes called sclerosing) and infiltrating subtypes showed the highest rates of cellular proliferation in a study measuring the fraction of actively dividing cells, while the familiar nodular BCC that most people picture had a lower proliferation rate.⁵ Superficial BCC, which tends to look like a flat red patch rather than a pearly bump, also scored relatively high on the proliferation index.

This matters practically because the subtype influences not just how fast a tumor grows outward but how deeply and irregularly it can invade. Nodular BCC, the most common subtype, tends to expand as a fairly well-defined mass, pushing into surrounding tissue in a predictable ball-like shape. Infiltrating and morpheic variants send thin strands of tumor cells into the surrounding dermis in patterns that are much harder to define on a clinical exam. A surgeon looking at an infiltrating BCC through a dermatoscope may see a tumor that looks small on the surface but has already extended well beyond its visible borders. That irregular invasion is one reason these subtypes carry a higher recurrence risk after standard excision.

Perineural Invasion

The most underappreciated way BCC spreads locally is along nerves, a process called perineural invasion. In a study of 244 BCC patients, perineural invasion was found in about one in five cases, with a related pattern of chronic inflammation around nerves present in roughly a third of patients.⁶ This form of spread was more common in larger tumors, deeper tumors, and those classified as high-risk subtypes.

When a BCC reaches a nerve sheath, it tends to travel along the nerve toward the nerve trunk rather than just growing outward in all directions. The rate of this axial spread along the nerve exceeds the concentric growth of the tumor itself.⁷ During Mohs surgery, tumors with perineural invasion required more surgical stages to clear, and the final wound area averaged over six times larger than that of tumors without nerve involvement. This is a striking illustration of how much hidden territory a BCC can cover beneath the surface.

One tricky feature of perineural spread is the appearance of “skip areas” on pathology: sections of nerve that look clear between stretches of tumor. Researchers believe these are artifacts of how the tissue is sliced rather than true gaps in tumor spread, which means a seemingly clear margin on one slice does not guarantee the nerve is actually tumor-free upstream. A systematic review pooling survival data on BCC with perineural invasion found that male sex, involvement of multiple nerves, the presence of clinical symptoms like numbness or pain, and nerve involvement visible on imaging were all associated with a worse prognosis.⁸ Early detection, before symptoms develop, is the best predictor of a good outcome.

Does BCC Actually Metastasize?

This is the question most people want answered when they hear the word “carcinoma.” For BCC, the honest answer is: almost never. Metastasis rates reported in the literature range from 0.0028% to 0.55%, depending on the study population and how rigorously cases were documented.⁹ A review of surgical cases at one institution put the figure at roughly one in a thousand.¹⁰ Given how common BCC is overall, even a fraction of a percent still translates to some real cases, but the individual risk is extremely low.

When metastasis does occur, the cancer tends to reach regional lymph nodes, lungs, bone, and skin.¹¹ The profile of a BCC most likely to metastasize is well characterized: it is typically a neglected tumor that has grown very large, often beyond five centimeters, and especially concerning once it exceeds ten centimeters. These so-called giant BCCs more commonly have aggressive histologic patterns, a history of prior treatment failures, and sometimes prior radiation exposure.¹² In other words, metastatic BCC is overwhelmingly a disease of neglect. Tumors caught and treated at a typical size carry a vanishingly small metastatic risk.

Giant BCCs and the Cost of Delay

It seems counterintuitive that the most common skin cancer in fair-skinned populations could ever reach a truly destructive size, but it happens. Case reports of giant BCCs eroding through cartilage, bone, or orbit are regularly published. The typical story involves a tumor that was present for ten to twenty years before the patient sought care.¹³ The patients in these reports are often elderly, socially isolated, or have psychiatric illness or severe health anxiety that kept them from seeing a doctor.

Because BCC grows slowly, there is a long window between “you should probably get that checked” and “this is now a surgical emergency.” That slow pace is paradoxically the problem: the tumor never alarms the patient the way a rapidly growing lump might. Year after year, a BCC that adds less than a centimeter annually can accumulate significant local destruction, especially on the face where important structures sit millimeters apart. The community-based study referenced earlier showed that BCCs continued to increase steadily in size over time with no evidence of a growth plateau.³ A tumor that goes unaddressed will keep going.

Immunosuppression and Genetic Syndromes

Your immune system plays an active role in keeping BCC in check. Rates of BCC are elevated in people who are immunosuppressed, such as organ transplant recipients on long-term anti-rejection drugs.¹⁴ The same research notes that BCCs can occasionally undergo spontaneous regression driven by the immune response, which underscores how much immune surveillance normally restrains this cancer. In an immunosuppressed person, BCCs tend to behave more aggressively, grow faster, and recur more often after treatment.

At the genetic extreme sits Gorlin syndrome, also called nevoid basal cell carcinoma syndrome. People with this inherited condition carry a mutation in the PTCH1 gene and can develop anywhere from a handful of BCCs to several thousand over their lifetime.¹⁵ Gorlin syndrome highlights the central role of the Hedgehog signaling pathway in BCC development. In sporadic (non-inherited) BCC, the same pathway is abnormally activated, and this constitutive activation appears to be essentially a prerequisite for BCC to develop at all.¹⁶ Understanding this pathway has led directly to targeted treatments, discussed below.

Recurrence After Treatment

Even after a BCC is removed, the story is not always over. In a retrospective study of patients treated with standard surgical excision, recurrences appeared anywhere from about eleven months to over seven years later, with a mean recurrence time of roughly two and a half years.¹⁷ That wide spread is one reason dermatologists recommend follow-up visits for several years after BCC treatment. A recurrence at two years is not unusual, but neither is one that shows up at five or six years.

Recurrent BCCs tend to behave more aggressively than the original tumor. They are more likely to display an infiltrative growth pattern and are more difficult to clear surgically because scar tissue from the first operation obscures their borders. When a previously treated BCC returns, Mohs micrographic surgery, which maps margins in real time during the procedure, is often preferred over standard excision precisely because of this margin uncertainty. Tumors with perineural invasion at initial treatment carry a particularly high rate of recurrence, reinforcing the point that nerve involvement changes the risk profile of what most people think of as a low-stakes cancer.

What Drives BCC Invasion at the Cellular Level

Researchers studying the boundary between BCC and the tissue it invades have found that stromal fibroblasts, the connective-tissue cells adjacent to the tumor, are actively reprogrammed by the cancer. These so-called cancer-associated fibroblasts remodel the structural matrix around the tumor in ways that support collective migration of cancer cells into surrounding tissue.¹⁸ In other words, the tumor does not just push through normal tissue like a wrecking ball. It recruits neighboring cells to clear a path. This helps explain why infiltrative BCC subtypes, which have a more active relationship with the surrounding stroma, spread locally with more irregular and harder-to-predict margins than nodular subtypes do.

Beyond the Hedgehog pathway, BCC cells also exploit Wnt signaling and the epidermal growth factor receptor (EGFR) pathway, both of which amplify tumor growth and survival signals. The convergence of these pathways helps explain why a BCC that has been present for years can sometimes seem to “wake up” and grow faster. Environmental shifts like increased sun exposure, local trauma, or immune suppression can tip the balance of these signaling networks in the tumor’s favor.

Hedgehog Pathway Inhibitors for Advanced BCC

For tumors that cannot be surgically removed or that have spread locally to the point where surgery would be devastating, drugs that block the Hedgehog pathway represent the current first-line systemic treatment.¹⁹ Two approved drugs, vismodegib and sonidegib, both target a protein in the Hedgehog cascade and can shrink or stabilize advanced BCCs that would otherwise continue to invade. A multicenter Italian study reported complete response rates of about 32% for vismodegib and 47% for sonidegib, with additional patients achieving partial responses.²⁰

These drugs have meaningful side effects, most commonly muscle cramps, hair loss, taste disturbances, and fatigue, and not every patient can tolerate long-term treatment. Additionally, resistance can develop over time: the tumor evolves mutations that allow Hedgehog signaling to bypass the drug’s blockade.²¹ Immunotherapy with checkpoint inhibitors is an emerging option for patients whose BCC progresses on Hedgehog inhibitors, though the evidence base is still developing. For the vast majority of patients whose BCC is caught at a typical stage, surgery alone resolves the problem, and systemic therapy never enters the conversation.

Sun Exposure and Where BCC Shows Up

Most BCCs arise on sun-exposed skin: the face, scalp, ears, neck, and forearms. Chronic ultraviolet exposure is the dominant environmental driver. However, BCCs do occasionally appear in sun-protected areas like the trunk, genital region, or soles of the feet. A study comparing sun-exposed and sun-protected BCCs found differences in the expression of the tumor-suppressor protein p16, with sun-protected tumors showing slightly higher positivity, though the difference was not statistically significant.²² The finding hints that the molecular underpinnings of BCC in protected areas may differ from the classic UV-driven model, though both types still rely on Hedgehog pathway activation.

For people worried about a spot that has been present for a while, the practical message is straightforward. BCC grows slowly enough that a few weeks between noticing something and seeing a dermatologist will not change your outcome. But it also grows steadily enough that a few years of avoidance will result in a bigger surgery, a more complex reconstruction, and a higher chance of recurrence. The optimal window is simply “sooner rather than later,” without panic but without procrastination.